Changes in Glucagon Levels After Four to Five Weeks of Glucoregulation by Portable Insulin Infusion Pumps

Near-normal glucoregulation was maintained in five patients with juvenile-onset diabetes mellitus for 4–5 wk with a preprogrammed, continuous, subcutaneous insulin infusion using a portable battery-powered infusion pump. This form of therapy significantly lowered immunoreactive glucagon (IRG) levels below those observed while on conventional insulin treatment at several times during the 24-h profile. The maximum IRG levels were also reduced in all five subjects. Thus, a flexible system of insulin delivery, as is provided by certain open-loop pump systems, can overcome inappropriate glucagon secretion that occurs with conventional insulin therapy.

[1]  W. Tamborlane,et al.  Normalization of the Growth Hormone and Catecholamine Response to Exercise in Juvenile-Onset Diabetic Subjects Treated with a Portable Insulin Infusion Pump , 1979, Diabetes.

[2]  K. Alberti,et al.  CONTINUOUS SUBCUTANEOUS INSULIN INFUSION: IMPROVED BLOOD-GLUCOSE AND INTERMEDIARY-METABOLITE CONTROL IN DIABETICS , 1979, The Lancet.

[3]  R. Rizza,et al.  Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. , 1979, The Journal of clinical investigation.

[4]  P. Raskin,et al.  Effects of insulin on the response of immunoreactive glucagon to an intravenous glucose load in human diabetes. , 1979, Metabolism: Clinical and Experimental.

[5]  W. Tamborlane,et al.  Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. , 1979, The New England journal of medicine.

[6]  M. Vranic,et al.  Effects of selective insulin or glucagon deficiency on glucose turnover. , 1979, The American journal of physiology.

[7]  K. Irsigler,et al.  Long-Term Continuous Intravenous Insulin Therapy with a Portable Insulin Dosage-regulating Apparatus , 1979, Diabetes.

[8]  P. Raskin,et al.  Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. , 1978, The New England journal of medicine.

[9]  P. Raskin,et al.  Abnormal alpha cell function in human diabetes: the response to oral protein. , 1978, The American journal of medicine.

[10]  W. Clarke,et al.  The Effect of Hyperglucagonemia on Blood Glucose Concentrations and on Insulin Requirements in Insulin-requiring Diabetes Mellitus , 1978, Diabetes.

[11]  P. Raskin,et al.  Effect of Insulin Therapy on the Profiles of Plasma Immunoreactive Glucagon in Juvenile-type and Adult-type Diabetics , 1978, Diabetes.

[12]  H Keen,et al.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. , 1978, British medical journal.

[13]  P. Felig,et al.  INFLUENCE OF SOMATOSTATIN ON CARBOHYDRATE DISPOSAL AND ABSORPTION IN DIABETES MELLITUS , 1976, The Lancet.

[14]  P. Raskin,et al.  Effect of Insulin on the Exaggerated Glucagon Response to Arginine Stimulation in Diabetes Mellitus , 1976, Diabetes.

[15]  E. Tsalikian,et al.  Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin. , 1975, The Journal of clinical endocrinology and metabolism.

[16]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.